Business Description
PROCEPT BioRobotics Corp
NAICS : 339112
SIC : 5047
ISIN : US74276L1052
Description
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, which are image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 3.87 | |||||
| Equity-to-Asset | 0.75 | |||||
| Debt-to-Equity | 0.21 | |||||
| Debt-to-EBITDA | -1.01 | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | 14.55 | |||||
| Beneish M-Score | -2.15 | |||||
| WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 27.2 | |||||
| 3-Year EBITDA Growth Rate | 20 | |||||
| 3-Year EPS without NRI Growth Rate | 21.7 | |||||
| 3-Year FCF Growth Rate | 17.3 | |||||
| 3-Year Book Growth Rate | 6.3 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 34.71 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 33.31 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 27.73 | |||||
| 9-Day RSI | 36.01 | |||||
| 14-Day RSI | 42.29 | |||||
| 3-1 Month Momentum % | 1.59 | |||||
| 6-1 Month Momentum % | -27.97 | |||||
| 12-1 Month Momentum % | -6.26 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 8.95 | |||||
| Quick Ratio | 7.75 | |||||
| Cash Ratio | 6.07 | |||||
| Days Inventory | 200.26 | |||||
| Days Sales Outstanding | 101.63 | |||||
| Days Payable | 47.14 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -7.8 | |||||
| Shareholder Yield % | -0.02 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 62.71 | |||||
| Operating Margin % | -38.7 | |||||
| Net Margin % | -36.2 | |||||
| EBITDA Margin % | -32.38 | |||||
| FCF Margin % | -35.41 | |||||
| ROE % | -29.12 | |||||
| ROA % | -20.64 | |||||
| ROIC % | -57.66 | |||||
| 3-Year ROIIC % | -26.68 | |||||
| ROC (Joel Greenblatt) % | -67.32 | |||||
| ROCE % | -22.16 | |||||
| Moat score | 4 | |||||
| Tariff score | 6 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 12.36 | |||||
| PB Ratio | 8.26 | |||||
| Price-to-Tangible-Book | 8.29 | |||||
| EV-to-EBIT | -33.6 | |||||
| EV-to-EBITDA | -35.9 | |||||
| EV-to-Revenue | 11.62 | |||||
| EV-to-Forward-Revenue | 29.31 | |||||
| EV-to-FCF | -32.83 | |||||
| Price-to-GF-Value | 0.58 | |||||
| Price-to-Net-Current-Asset-Value | 9.58 | |||||
| Price-to-Net-Cash | 17.32 | |||||
| Earnings Yield (Greenblatt) % | -2.98 | |||||
| FCF Yield % | -2.74 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers